Researchers from the Spanish National Cancer Research Centre, in collaboration with the University of Cambridge and Tailor Bio, have developed a novel genomic test capable of predicting chemotherapy resistance across pan-cancer types. This approach leverages chromosomal instability signatures to identify patients unlikely to benefit from platinum-based, taxane, or anthracycline chemotherapies. By stratifying patients based on genomic biomarkers, this innovation aims to reduce exposure to ineffective, toxic treatments, enhancing personalized oncology and potentially lowering healthcare costs. The test, published in leading journals, combines advanced DNA sequencing with computational modeling, marking a significant advance in precision cancer medicine.